Oventus Medical Ltd (ASX:OVN) will unveil latest advancements in the field, which are changing the way the disease is treated, in San Francisco next week (April 20th). Dr Chris Hart will join more than 30 international speakers at 3DHEALS2017 - the first collaborative conference in the U.S. aiming to create a global healthcare community focusing on 3D printing and related technologies.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth whilst alleviating multiple sites of obstruction including the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2VentTM T is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present; breathing is supplemented via the airways in the appliance. According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnea. Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.
Oventus Medical Ltd (ASX:OVN) Investor Update: Achieves Significant Milestones in Last Quarter and Expands Commercialisation of O2Vent T
Oventus Medical Ltd (ASX:OVN) are pleased to provide the Company's latest Investor Update. Oventus have achieved a number of significant milestones in the last quarter, expanding the commercialisation efforts of our O2Vent(TM) T device in numerous geographical regions and strengthening our sales and operational systems.
During the half-year the principal activities of Oventus Medical Ltd (ASX:OVN) (the Company) consisted of the commercialisation and distribution of the O2Vent(TM) T, in Australia, as well as development of a pipeline or products to treat segments of the snoring and sleep and apnoea market.
Oventus Medical Limited (ASX:OVN) today announced that it is the lead participant in a successful application for a grant in the 2nd round of the CRC-P grants that from the Australian Federal Government. The project will receive $2,950,000 over three years for a project titled, "Targeted therapy for sleep apnoea: A novel personalised approach".